Actively Recruiting
Randomized Trial Comparing Trastuzumab-Emtansine Followed by Subcutaneous Trastuzumab Versus Paclitaxel Plus Subcutaneous Trastuzumab for Stage I HER2-Positive Breast Cancer
Led by Dana-Farber Cancer Institute · Updated on 2026-08-19
500
Participants Needed
53
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.
CONDITIONS
Brief Title
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Research Team
S
Sara Tolaney, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here